Search Within

Maurizio Scaltriti

Formats
  1. Journal Article (94)
  2. Meeting Abstract (68)
  3. Book Section (3)
  4. Review (3)
  5. Guidelines (1)
  6. Research Letter (1)
Groups
  1. GSK Faculty (89)
  2. Sloan Kettering Institute Postdocs (86)
  3. Department of Medicine (80)
  4. Solid Tumor Oncology Division (79)
  5. Human Oncology and Pathogenesis Program (60)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (55)

More Groups

People
  1. Jose Baselga (63)
  2. Pedram Razavi (32)
  3. David Hyman (27)
  4. Michael Berger (27)
  5. Sarat Chandarlapaty (26)
  6. Emiliano Cocco (25)

More People

Years
  1. 2025 (1)
  2. 2023 (2)
  3. 2022 (6)
  4. 2021 (16)
  5. 2020 (27)
  6. 2019 (26)

More Years

Publications
  1. Cancer Research (37)
  2. Annals of Oncology (16)
  3. Clinical Cancer Research (12)
  4. Cancer Discovery (8)
  5. Journal of Clinical Oncology (8)
  6. Cancer Cell (6)

More Publications

Publishers
  1. American Association for Cancer Research (59)
  2. Nature Publishing Group (20)
  3. Oxford University Press (17)
  4. Elsevier Inc. (12)
  5. American Association for the Advancement of Science (10)
  6. American Society of Clinical Oncology (9)

More Publishers

Results (170)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Biomarkers of drugs targeting HER-family signalling in cancer
    Journal Article

    Montemurro, F.; Scaltriti, M.
    Journal of Pathology (2014)

    Fulltext@MSK | Save
  • Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer
    Meeting Abstract

    Montemurro, F.; Prat, A.; Rossi, V.; Valabrega, G.; Sperinde, J.; Peraldo-Neia, C.; Donadio, M.; Galvan, P.; Sapino, A.; Aglietta, M.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • High HER2 expression correlates with response to trastuzumab and the combination of trastuzumab and lapatinib in the NeoALTTO phase III trial
    Meeting Abstract

    Scaltriti, M.; Nuciforo, P.; Bradbury, I.; Sperinde, J.; Serra, V.; Parra, J. L.; Prudkin, L.; Harbeck, N.; Pusztai, L.; Ellis, C.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Combined blockade of PI3K/AKT and EGFR/HER3 enhances antitumor activity in triple negative breast cancer
    Meeting Abstract

    Scaltriti, M.; Tao, J.; Juric, D.; Auricchio, N.; Castel, P.; Morse, N.; Kim, P.; Singh, S.; Hazra, S.; Hembrough, T.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Sensitivity to combined MEK and mTORC1/2 inhibition in colorectal cancer is dictated by p53 mutational status
    Meeting Abstract

    Garcia-Garcia, C.; Rivas, M. A.; Ibrahim, Y. H.; Calvo, M. T.; Grueso, J.; Antón, P.; Aura, C.; Jessen, K.; Palmer, H.; Tabernero, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save
  • Evaluation and clinical analyses of downstream targets of the akt inhibitor GDC-0068
    Journal Article

    Yan, Y.; Serra, V.; Prudkin, L.; Scaltriti, M.; Murli, S.; Rodríguez, O.; Guzman, M.; Sampath, D.; Nannini, M.; Xiao, Y.; more...
    Clinical Cancer Research (2013)

    Fulltext@MSK | Save
  • Clinical response to a lapatinib-based therapy for a Li-Fraumeni Syndrome patient with a novel HER2V659E mutation
    Journal Article

    Serra, V.; Vivancos, A.; Puente, X. S.; Felip, E.; Silberschmidt, D.; Caratù, G.; Parra, J. L.; De Mattos-Arruda, L.; Grueso, J.; Hernández-Losa, J.; more...
    Cancer Discovery (2013)

    Fulltext@MSK | Save
  • MTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
    Journal Article

    Elkabets, M.; Vora, S.; Juric, D.; Morse, N.; Mino-Kenudson, M.; Muranen, T.; Tao, J.; Bosch Campos, A.; Rodon, J.; Ibrahim, Y. H.; more...
    Science Translational Medicine (2013)

    Fulltext@MSK | Save
  • RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
    Journal Article

    Serra, V.; Eichhorn, P. J. A.; García-García, C.; Ibrahim, Y. H.; Prudkin, L.; Sánchez, G.; Rodriguez, O.; Antón, P.; Parra, J. L.; Marlow, S.; more...
    Journal of Clinical Investigation (2013)

    Fulltext@MSK | Save
  • Reactivation of oncogenic signaling through mTOR inhibitors-induced feedback adaptations
    Meeting Abstract

    Rodrik-Outmezguine, V.; Chandarlapaty, S.; Poulikakos, P.; Scaltriti, M.; Baselga, J.; Rosen, N.
    Cancer Research (2012)

    Fulltext@MSK | Save